| Brandenberg, Nathalie (Sun Bioscience 202310 Co-CEO + Co-Founder) |
Chief Executive Officer (CEO) |
|
Epalinges VD |
| Hoehnel, Sylke (Sun Bioscience 202310 Co-CEO + Co-Founder) |
Chief Executive Officer (CEO) |
|
Epalinges VD |
| Leo, Giovanni (EFI Lake Geneva Ventures I 202306 Partner + EBAMed 202306 Co-Founder + Chair) |
Partner (venture partner) |
|
|
| van den Oever, Jeroen (Sun Bioscience 202310 CFO) |
Chief Executive Officer (CEO) |
|
Epalinges VD |
| Scherer, Stefan J. (3T Biosciences 202301 formerly Biocartis + Roche/Genentech + Grünenthal) |
Chief Executive Officer (CEO) |
3T Biosciences Inc. |
South San Francisco, CA |
| Cunha, Fernando (AB2 Bio 201602 CFO) |
Chief Financial Officer (CFO) |
AB2 Bio S.A. |
Lausanne VD |
| Sleight, Andrew (AB2 Bio 201602 CEO before 21y at Roche) |
Chief Executive Officer (CEO) |
AB2 Bio S.A. |
Lausanne VD |
| Bolliger, Luca (Novimmune 201012 Director Business Development + Communication) |
Company Founder |
abcDNA GmbH |
Luzern LU |
| Siffert, João (Abeona 201811– Interim CEO before Head RnD + CMO before AveXis + Ceregene + Avanir + Avera + Nestlé) |
Chief Executive Officer (CEO) |
Abeona Therapeutics Inc. (Nasdaq: ABEO) |
New York, NY |
| Durand, Nicolas (Abionic 201604 CEO + Co-Founder) |
Chief Executive Officer (CEO) |
Abionic S.A. |
Epalinges VD |
| Märki, Iwan (Abionic 201909 CTO) |
Chief Technology/Technical Officer (CTO) |
Abionic S.A. |
Epalinges VD |
| Rebeaud, Fabien (Abionic 201909 CSO) |
Chief Scientific Officer (CSO) / Chief Development Officer (CDO) |
Abionic S.A. |
Epalinges VD |
| Derouazi, Madiha (AC Immune 202401–CSO before Speransa Therapeutics + Amal Therapeutics) |
Chief Scientific Officer (CSO) / Chief Development Officer (CDO) |
AC Immune S.A. (Nasdaq: ACIU) |
Lausanne VD |
| Monin, Jean-Fabien (AC Immune 200901– CFO before 14y at bioMérieux CFO Central Europe) |
Chief Financial Officer (CFO) |
AC Immune S.A. (Nasdaq: ACIU) |
Lausanne VD |
| Moore, Judith (AC Immune 202003 Global Head of Communications) |
Public Relations Manager / Investor Relations Manager |
AC Immune S.A. (Nasdaq: ACIU) |
Lausanne VD |
| Roberts, Christopher (Chris) (AC Immune 202401– promoted to CFO joined 2019) |
Chief Financial Officer (CFO) |
AC Immune S.A. (Nasdaq: ACIU) |
Lausanne VD |
| Schier, Eva (AC Immune 201605 Corporate Communciations Manager) |
public relations / investor relations |
AC Immune S.A. (Nasdaq: ACIU) |
Lausanne VD |
| Velasco, Martin (AC Immune 201401 Board Chairman) |
Board member, non-executive |
AC Immune S.A. (Nasdaq: ACIU) |
Lausanne VD |
| Carmona, Jose I. (Pepe) (ADC Therapeutics 202212– CFO before Rubius Therapeutics + Radius Health + Innocoll + Novartis) |
Chief Financial Officer (CFO) |
ADC Therapeutics (Group) |
Epalinges VD |
| Creel, Jennifer (Jenn) (ADC Therapeutics 202004– CFO before Celgene + Watson Pharmaceuticals + Pfizer) |
Chief Financial Officer (CFO) |
ADC Therapeutics (Group) |
Epalinges VD |
| Forer, Michael (Celtic Therapeutics 201207 CEO of ADC Therapeutics until 6/15 + Partner in Celtic Therapeutics) |
Chief Executive Officer (CEO) |
ADC Therapeutics (Group) |
Lausanne VD |
| Gilman, David (ADC Therapeutics 202206– Chief Business + Strategy Officer before ClearView Healthcare Partners) |
Business Development Manager / Strategy Manager |
ADC Therapeutics (Group) |
Epalinges VD |
| Gonçalves, Dulce (Auven Therapeutics 201409– Corporate Counsel at ADC Therapeutics before Novartis) |
General Counsel / Chief Legal Officer (CLO) |
ADC Therapeutics (Group) |
Lausanne VD |
| Graham, Peter (ADC Therapeutics 202211– Chief Legal Officer before Halozyme Therapeutics + Delcath Systems) |
General Counsel / Chief Legal Officer (CLO) |
ADC Therapeutics (Group) |
Epalinges VD |
| Harrington-Smith, Kristen (ADC Therapeutics 202211– CCO before Immunogen + Novartis Pharmaceuticals) |
Chief Commercial Officer (CCO) |
ADC Therapeutics (Group) |
Epalinges VD |
| Henchoz, Stéphane (Auven Therapeutics 201409– Director of Finance at ADC Therapeutics before Merck Serono) |
Chief Financial Officer (CFO) |
ADC Therapeutics (Group) |
Lausanne VD |
| Litz, Eugenia (ADC Therapeutics 202201 before Ipsen + AstraZeneca + BioMarin + Thomas Weisel + Avondale Partners) |
Public Relations Manager / Investor Relations Manager |
ADC Therapeutics (Group) |
Epalinges VD |
| Loshbaugh, Amanda (ADC Therapeutics 202301 Investor Relations) |
Public Relations Manager / Investor Relations Manager |
ADC Therapeutics (Group) |
Epalinges VD |
| Mallik, Ameet (ADC Therapeutics 202205– CEO before Rafael Holdings + 16y at Novartis + McKinsey & Co) |
Chief Executive Officer (CEO) |
ADC Therapeutics (Group) |
Epalinges VD |
| Martin, Chris (Auven Therapeutics 201506 CEO of ADC Therapeutics before CEO of Spirogen Ltd) |
Managing Director |
ADC Therapeutics (Group) |
Lausanne VD |
| Ondish, Mary Ann (ADC Therapeutics 202206 Media Relations) |
Public Relations Manager / Investor Relations Manager |
ADC Therapeutics (Group) |
Epalinges VD |
| Riley, Nicole (ADC Therapeutics 202307 Media Relations) |
Public Relations Manager / Investor Relations Manager |
ADC Therapeutics (Group) |
Epalinges VD |
| Sandor, Victor (ADC Therapeutics 202004– Board Director before CMO at Array BioPharma + Incyte + Biogen Idec + AZ) |
Board member, non-executive |
ADC Therapeutics (Group) |
Epalinges VD |
| van Berkel, Patrick (Celtic Therapeutics 201207– SVP RnD of ADC Therapeutics before Genmab + Crucell + Pharming) |
Research & Development Manager |
ADC Therapeutics (Group) |
Lausanne VD |
| Dyer, Tim (Addex CEO 201802 formerly CFO + Co-Founder) |
Chief Executive Officer (CEO) |
Addex (Group) |
Genève (Geneva) GE |
| Epping-Jordan, Mark (Addex Pharma –200806 CSO) |
Chief Scientific Officer (CSO) / Chief Development Officer (CDO) |
Addex (Group) |
Plan-les-Ouates GE |
| Lütjens, Robert (Addex 201802 Head of Discovery) |
management (personnel) |
Addex (Group) |
Genève (Geneva) GE |
| Massuyeau, Laurent (Addex 200804–200909 Head Business Developm before Idenix RESIGNED 9/09 at Addex) |
Business Development Manager / Strategy Manager |
Addex (Group) |
Plan-les-Ouates GE |
| Mills, Roger G. (Addex 201611– CMO before Acadia Pharmaceuticals + Pfizer + Gilead + Abbott + Wellcome) |
Chief Medical Officer (CMO) |
Addex (Group) |
Genève (Geneva) GE |
| Mueller, André J. (Addex 201106 Chairman of the Board before Actelion CFO before Biogen before Sandoz) |
Board member, non-executive |
Addex (Group) |
Plan-les-Ouates GE |
| Mutel, Vincent (Addex 2002c–201106 CEO stepped down 6/11) |
Chief Executive Officer (CEO) |
Addex (Group) |
Plan-les-Ouates GE |
| Poli, Sonia (Addex 201501 CSO) |
Chief Scientific Officer (CSO) / Chief Development Officer (CDO) |
Addex (Group) |
Genève (Geneva) GE |
| Rocher, Jean-Philippe (Addex 201802– Co-Head Disovery before Pierre Fabre + Addex + Devgen + GSK Japan + Batelle) |
management (personnel) |
Addex (Group) |
Genève (Geneva) GE |
| Affentranger, Anton (Affentranger Associates 200803 CEO + Senior Partner + founder before Roche CFO) |
Chief Executive Officer (CEO) |
Affentranger Associates S.A. |
Genève (Geneva) GE |
| Fulpius, Nicolas (Affentranger Associates 200803 Partner before Ultreia Capital Investment Director) |
Partner (venture partner) |
Affentranger Associates S.A. |
Genève (Geneva) GE |
| Siegel, Oliver (Affiris 201506– CEO joined 201409 as COO before Rothschild in London + HSBC plc) |
Chief Executive Officer (CEO) |
Affiris AG |
Wien (Vienna) |
| Decouttere, Frederik (Genohm 2010– CEO before CTO + Co-Founder) |
Chief Executive Officer (CEO) |
Agilent (Group) |
Lausanne VD |
| Van den Berghe, Jan (Novalis Biotech 202205 Manaing Director + Co-Founder formerly Genohm 201503) |
Managing Director |
Agilent (Group) |
Lausanne VD |
| Mercanzini, André (Aleva Neurotherapeutics 201108 CTO) |
Chief Technology/Technical Officer (CTO) |
Aleva Neurotherapeutics S.A. |
Lausanne VD |
| Rosat, Jean-Pierre (Aleva Neurotherapeutics 201108 CEO) |
Chief Executive Officer (CEO) |
Aleva Neurotherapeutics S.A. |
Lausanne VD |
| Stuge, Örn (Aleva Neurotherapeutics 201108 Chairmen Board of Directors) |
Board member, non-executive |
Aleva Neurotherapeutics S.A. |
Lausanne VD |
| Dainese, Riccardo (Alithea Genomics 202205 CEO + Co-Founder) |
Chief Executive Officer (CEO) |
Alithea Genomics S.A. |
Epalinges VD |
| Yakneen, Sergei (Alphabet 202205– CTO at Isomorphic Labs before Sophia Genetics + Amazon + BPS) |
Chief Technology/Technical Officer (CTO) |
Alphabet (formerly Google) (Group) |
London, Greater London |
| Rinsch, Chris (Amazentis 202209 CEO + Co-Founder) |
Chief Executive Officer (CEO) |
Amazentis S.A. |
Lausanne VD |
| Watons, John A. (SomPharmaceuticals SA 201411 CEO) |
Chief Executive Officer (CEO) |
Amryt Pharma (Group) |
Epalinges VD |
| Charlon, Vincent (Anergis 201103 CEO) |
Chief Executive Officer (CEO) |
Anergis S.A. |
Epalinges VD |
| Reymond, Christophe (Anergis 201103 CSO) |
Chief Scientific Officer (CSO) / Chief Development Officer (CDO) |
Anergis S.A. |
Epalinges VD |
| Simonsen, Kim (Anergis 201506– Chief Development Officer before Ablynx + ALK-Abello + Medicon A/S + Novartis) |
Chief Scientific Officer (CSO) / Chief Development Officer (CDO) |
Anergis S.A. |
Epalinges VD |
| Spertini, Francois (Anergis 2007 President Board of Directors) |
President/Director/Head Business Group/Unit/Division |
Anergis S.A. |
Epalinges VD |
| Geraghty, Deborah (Anokion 202210 CEO) |
Chief Executive Officer (CEO) |
Anokion (Group) |
Ecublens VD |
| Hubbell, Jeffrey A. (Anokion 201701 Chairman + CSO + Academic Founder + Prof at Univ Chicago + before at EPFL) |
Chief Scientific Officer (CSO) / Chief Development Officer (CDO) |
Anokion (Group) |
Ecublens VD |
| Botti, Paolo (Arisgen 2007) |
n. a. |
ArisGen S.A. |
Plan-les-Ouates GE |
| Beher, Dirk (Asceneuron 201509 CEO) |
Chief Executive Officer (CEO) |
Asceneuron S.A. |
Lausanne VD |
| Ryan, J. Michael (Asceneuron 201704 CMO) |
Chief Medical Officer (CMO) |
Asceneuron S.A. |
Lausanne VD |
| Wiessner, Christoph (Asceneuron 201509 COO) |
Chief Operating Officer (COO) |
Asceneuron S.A. |
Lausanne VD |
| Theurillat, Jacques (Ares Life Sciences CEO before Serono) |
Chief Executive Officer (CEO) |
BERTARELLI Group (family of Ernesto Bertarelli) |
Genève (Geneva) GE |
| Wohlwend, Frédéric (Bertorelli Group 201905 Managing Partner at Forestay Capital before Merck (DE) + Serono) |
Managing Partner (investment firm) |
BERTARELLI Group (family of Ernesto Bertarelli) |
Genève (Geneva) GE |
| Büchler, Andrea (Lunaphore 201808 Finance + Business Development) |
Business Development Manager / Strategy Manager |
Bio-Techne (Group) |
Lausanne VD |
| Ciftlik, Ata Tuna (Lunaphore Technologies 201404– CEO + Co-Founder) |
Chief Executive Officer (CEO) |
Bio-Techne (Group) |
Lausanne VD |
| Heintze, Déborah (Lunaphore Technologies 201404– COO + Co-Founder) |
Chief Operating Officer (COO) |
Bio-Techne (Group) |
Lausanne VD |
| Mounier, Théophile (Lunaphore 202105 Corporate Finance) |
Financial Manager (CFO, Financial Director, etc.) |
Bio-Techne (Group) |
Lausanne VD |
| Tamayo, Irene (Lunaphore 201808 Corporate Communications) |
public relations / investor relations |
Bio-Techne (Group) |
Lausanne VD |
| Cordes, Ulrik (Biocartis 201309– CCO before Thermo Fisher + Dako A/S + Pharmacia Biotech A/S) |
Chief Commercial Officer (CCO) |
Biocartis (Group) |
Lausanne VD |
| Harrison, Clark (Biocartis 201201– COO before Leica Biosystems VP Global Operations) |
Chief Operating Officer (COO) |
Biocartis (Group) |
Lausanne VD |
| Parekh, Nayan Gregory (Biocartis 201111– CEO before Executive Director before New Rhein Healtchare + Novartis) |
Chief Executive Officer (CEO) |
Biocartis (Group) |
Lausanne VD |
| Pauwels, Rudi (Biocartis 201111 Executive Chairman before 201002–201111 CEO) |
Chief Executive Officer (CEO) |
Biocartis (Group) |
Lausanne VD |
| Windels, Hilde (Biocartis 201107– CFO + managing director Biocartis NV before Devgen 1999–2008 CFO) |
Chief Financial Officer (CFO) |
Biocartis (Group) |
Lausanne VD |
| Maggos, Chris (BioConfidant / Cohesion Bureau 202303 Managing Director + Founder before LifeSci Advisors + Addex) |
Public Relations Manager / Investor Relations Manager |
BioConfidant (Group) |
Genève (Geneva) GE |
| Bonnet, Frank (Bionomous 202208 CEO + Co-Founder) |
Chief Executive Officer (CEO) |
Bionomous S.A. |
Lausanne VD |
| Hernando Ariza, Ana (Bionomous 202208 COO + Co-Founder) |
Chief Operating Officer (COO) |
Bionomous S.A. |
Lausanne VD |
| de Schoulepnikoff, Laurence (Tridek-One 202207– CEO before Amal Therapeutics) |
Chief Business Officer (CBO) |
Boehringer Ingelheim (Group) |
Genève (Geneva) GE |
| Essinger, Jacques R. (Symetis 201703 CEO) |
Chief Executive Officer (CEO) |
Boston Scientific (Group) |
Ecublens VD |
| Kreitman, Benjamin (Broadview Ventures 202105) |
Investment Manager |
Broadview Ventures Inc. |
Boston, MA |
| Donoghue, John P. (Brown University 201408 Professor + Wyss Center at Campus Biotech Geneva) |
Professor |
Brown University |
Providence, RI |
| Füglister, Michael (Cabinet Privé de Conseils 202009) |
Public Relations Manager / Investor Relations Manager |
Cabinet Privé de Conseils S.A. |
Genève (Geneva) GE |
| Kull, Toomas (Cabinet Privé de Conseils 202009) |
Public Relations Manager / Investor Relations Manager |
Cabinet Privé de Conseils S.A. |
Genève (Geneva) GE |
| Miles, Nick (Cabinet Privé de Conseils 202009) |
Public Relations Manager / Investor Relations Manager |
Cabinet Privé de Conseils S.A. |
Genève (Geneva) GE |
| Elger, Daniel (Genkyotec 201406– CFO + Chief Development Officer before e-Therapeutics plc + Antisoma) |
Chief Financial Officer (CFO) |
Calliditas Therapeutics (Group) |
Plan-les-Ouates GE |
| Ney, Ursula M. (Genkyotex 201105– CEO before Antisoma COO before Charterhouse Therapeutics CEO) |
Chief Executive Officer (CEO) |
Calliditas Therapeutics (Group) |
Plan-les-Ouates GE |
| Wiesel, Philippe (AgomAb Therapeutics 202103– CMO before Genkyotex + Serono in US + CH) |
Chief Medical Officer (CMO) |
Calliditas Therapeutics (Group) |
Plan-les-Ouates GE |
| Dubuis, Benoît (Campus Biotech Geneva 201601 Site Director) |
President/Director/Head Business Group/Unit/Division |
Campus Biotech Innovation Center (Geneva, former Merck Serono site) |
Genève (Geneva) GE |
| Schnee, Elmar (Cardiorentis 201110– CEO before Merck Serono S.A. 200701 CEO before Merck KGaA) |
Chief Executive Officer (CEO) |
Cardiorentis (Group) |
Zug ZG |
| Boulanger, Dimitri (Céleste Management 202012 CEO) |
Chief Executive Officer (CEO) |
Céleste Management S.A. |
Genève (Geneva) GE |
| Deperthes, David (Debiopharm 201306 VP Business Development) |
Business Development Manager / Strategy Manager |
Debiopharm (Group) |
Lausanne VD |
| Ducrey, Bertrand (Debiopharm 201610 CEO of Debiopharm International) |
Chief Executive Officer (CEO) |
Debiopharm (Group) |
Lausanne VD |
| Dumont, Jean-Maurice (Debiopharm 201504 VP Medical Affairs) |
Chief Medical Officer (CMO) |
Debiopharm (Group) |
Lausanne VD |
| Levy, Frederic (Debiopharm 202003 Executive Director of Search + Evaluation + Scientific Innovation) |
n. a. |
Debiopharm (Group) |
Lausanne VD |
| Mauvernay, Rolland-Yves (Debiopharm 201301 President + Founder) |
President/Director/Head Business Group/Unit/Division |
Debiopharm (Group) |
Lausanne VD |
| Mauvernay, Thierry (Debiopharm 201306 Board Member) |
Board member |
Debiopharm (Group) |
Lausanne VD |
| McAllister, Andres (Debiopharm 201306 CSO Resesearch + Evaluation) |
Chief Scientific Officer (CSO) / Chief Development Officer (CDO) |
Debiopharm (Group) |
Lausanne VD |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
